Axogen, Inc.
AXGNNasdaq
$39.85
↑ +0.2%Jul 17 close · end-of-day
Price
1Y↑ +237.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.1B
Enterprise Value
$2.0B
P/E
—
P/S
8.6
P/B
8.4
EV/EBITDA
—
PEG
—
FCF Yield
0.4%
Dividend Yield
—
Revenue (TTM)
$238.1M
Net Income (TTM)
-$31.5M
Free Cash Flow (TTM)
$9.3M
Gross Margin
75.0%
Operating Margin
-3.8%
Net Margin
-13.2%
ROE
-12.8%
ROIC
-5.0%
Debt / Equity
0.0
Net Cash
$101.6M
Return 1Y
+242.6%
Company profile
AxoGen, Inc. develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site. AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves, is used to wrap and protect damaged peripheral nerves and reinforces the nerve reconstruction while preventing soft tissue attachments.
- CEO
- Karen L. Zaderej
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 450
- Headquarters
- Florida
- Website
- axogeninc.com
Management & directors
- Hartley Lindsey MarieCFO
- Kemp JensChief Marketing Officer
- Quackenbush DorisSales VP
- Devinney Erick WayneChief Innovation Officer
- Began Marc AEVP & General Counsel
- Dale Michael DChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
AXGN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$61.5M↑ +26.6%
Diluted EPS-$0.38↑ +375.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $112.3M | $127.4M | $138.6M | $159.0M | $187.3M | $225.2M |
| Gross profit | $90.7M | $104.4M | $108.8M | $121.9M | $142.0M | $167.4M |
| Operating income | -$23.2M | -$25.4M | -$29.7M | -$21.5M | -$3.3M | -$7.8M |
| Net income | -$23.8M | -$27.0M | -$28.9M | -$21.7M | -$10.0M | -$15.7M |
| Diluted EPS | -$0.60 | -$0.65 | -$0.69 | -$0.51 | -$0.23 | -$0.34 |
| Operating cash flow | -$9.6M | -$13.4M | -$16.1M | -$5.7M | $4.5M | $812,000.00 |
| Free cash flow | -$31.5M | -$41.2M | -$36.1M | -$19.6M | $1.4M | -$2.9M |
| Gross margin | 80.8% | 82.0% | 78.5% | 76.6% | 75.8% | 74.3% |
| Operating margin | -20.6% | -20.0% | -21.4% | -13.5% | -1.8% | -3.5% |
| Net margin | -21.2% | -21.2% | -20.9% | -13.7% | -5.3% | -7.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $47.9M | $48.6M | $49.4M | $48.6M | $56.7M | $60.1M | $59.9M | $61.5M |
| Gross profit | $35.3M | $36.4M | $37.6M | $34.9M | $42.0M | $46.0M | $44.4M | $46.2M |
| Operating income | -$428,000.00 | -$316,000.00 | $2.0M | -$1.7M | $1.7M | $1.9M | -$9.8M | -$2.8M |
| Net income | -$1.9M | -$1.9M | $450,000.00 | -$3.8M | $579,000.00 | $708,000.00 | -$13.2M | -$19.6M |
| Diluted EPS | -$0.04 | -$0.04 | $0.00 | -$0.08 | $0.01 | $0.01 | -$0.28 | -$0.38 |
| Operating cash flow | $4.2M | $3.9M | $8.7M | -$13.2M | $7.7M | $3.2M | $3.0M | $1.6M |
| Free cash flow | $3.3M | $3.3M | $8.1M | -$13.4M | $7.0M | $1.7M | $1.8M | -$1.2M |
| Gross margin | 73.8% | 74.9% | 76.1% | 71.9% | 74.2% | 76.6% | 74.1% | 75.2% |
| Operating margin | -0.9% | -0.6% | 4.1% | -3.4% | 3.0% | 3.2% | -16.3% | -4.6% |
| Net margin | -4.0% | -3.8% | 0.9% | -7.9% | 1.0% | 1.2% | -22.0% | -31.9% |
Company news
Jul 15, 2026
Jun 6, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-19 | Levine Alan M | Option exercise | 14,150 | $0.00 | $0.00 | filing |
| 2026-06-19 | Weiler Kathy Johnson | Option exercise | 14,150 | $0.00 | $0.00 | filing |
| 2026-06-19 | Wendell Amy McBride | Option exercise | 14,150 | $0.00 | $0.00 | filing |
| 2026-06-19 | THOMAS PAUL | Option exercise | 18,867 | $0.00 | $0.00 | filing |
| 2026-06-19 | TYNDALL JOSEPH A. | Option exercise | 14,150 | $0.00 | $0.00 | filing |
| 2026-06-19 | JOHNSON JOHN | Option exercise | 14,150 | $0.00 | $0.00 | filing |
| 2026-06-19 | Burke Willaim P | Option exercise | 14,150 | $0.00 | $0.00 | filing |
| 2026-05-08 | Wendell Amy McBride | Sale | 1,647 | $42.60 | $70,162.20 | filing |
| 2026-05-08 | Wendell Amy McBride | Option exercise | 1,647 | $14.85 | $24,457.95 | filing |
| 2026-05-07 | Weiler Kathy Johnson | Sale | 16,344 | $44.09 | $720,623.30 | filing |
| 2026-05-07 | JOHNSON JOHN | Sale | 11,050 | $43.26 | $477,967.75 | filing |
| 2026-05-07 | Kemp Jens· Chief Marketing Officer | Sale | 4,000 | $43.44 | $173,761.20 | filing |
| 2026-05-07 | Quackenbush Doris· Sales VP | Sale | 3,878 | $43.51 | $168,720.15 | filing |
| 2026-05-07 | Weiler Kathy Johnson | Option exercise | 16,344 | $6.95 | $113,590.80 | filing |
| 2026-05-07 | JOHNSON JOHN | Option exercise | 11,050 | $7.04 | $77,792.00 | filing |
| 2026-05-07 | Hartley Lindsey Marie· CFO | Sale | 573 | $43.67 | $25,022.91 | filing |
| 2026-05-07 | Hartley Lindsey Marie· CFO | Option exercise | 2,963 | $8.27 | $24,504.01 | filing |
| 2026-05-07 | Hartley Lindsey Marie· CFO | Sale | 478 | $43.67 | $20,874.26 | filing |
| 2026-05-07 | Hartley Lindsey Marie· CFO | Option exercise | 2,500 | $8.20 | $20,500.00 | filing |
| 2026-03-16 | DeVinney Erick Wayne· Chief Innovation Officer | Sale | 5,221 | $32.84 | $171,457.64 | filing |
| 2026-03-16 | DeVinney Erick Wayne· Chief Innovation Officer | Tax withholding | 2,870 | $32.84 | $94,250.80 | filing |
| 2026-03-16 | Hartley Lindsey Marie· CFO | Tax withholding | 1,968 | $32.84 | $64,629.12 | filing |
| 2026-03-16 | Hartley Lindsey Marie· CFO | Tax withholding | 1,574 | $32.84 | $51,690.16 | filing |
| 2026-03-16 | DeVinney Erick Wayne· Chief Innovation Officer | Option exercise | 11,575 | $0.00 | $0.00 | filing |
| 2026-03-16 | Hartley Lindsey Marie· CFO | Option exercise | 4,000 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.